Clinical Trials Browser

Phase 2 × Completed × Hereditary Sensory and Autonomic Neuropathies × Clear all

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05054725 2026-01-06

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Phase 2 Completed

54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

NCT03126019 2025-03-14

CITADEL-203

Phase 2 Completed

126 enrolled 15 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies

NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Phase 2 Completed

76 enrolled 42 charts

Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

NCT01320085 2024-01-24

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Phase 2 Completed

183 enrolled 35 charts

Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT01640444 2019-04-11

VISNU-2

Phase 2 Completed

240 enrolled

Gastrointestinal

Neoplastic Cells, Circulating, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Clinical Trials

BYLieve

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

CITADEL-203

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

VISNU-2